| Title | Author(s) | Year | View Count |
 | A phase IIb study of the efficacy and safety of LB80380 vs entecavir in treatment-naive patients with chronic hepatitis B | Lai, CL; Ahn, SH; Lee, KS; Um, SH; Cho, M; Yoon, SK; Lee, JW; Park, NW; Kwon, YO; Sohn, JH; Lee, JY; Park, HE; Kim, JA; Han, KH; Yuen, MF | 2011 | 205 |
| Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B | Lai, CL; Ahh, SH; Lee, KS; Um, SH; Cho, M; Yoon, SK; Lee, JW; Park, NH; Kweon, YO; Sohn, JH; Lee, J; Kim, JA; Han, KH; Yuen, MF | 2011 | 51 |
| Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease | Yuen, MF; Han, KH; Um, SH; Yoon, SK; Kim, HR; Kim, J; Kim, CR; Lai, CL | 2010 | 57 |
 | Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV | Lai, CL; Han, KH; Yoon, SK; Um, SH; Yuen, MF; Kim, HS; Kim, HR; Chung, HC; Kim, CR; Hsyu, P; Averett, D; Worland, S; Kim, J | 2006 | 197 |
|
